Imaging for treatment optimization in advanced prostate cancer
Single-Photon Emission Computed Tomography (SPECT) Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization (SEEtoTREAT)
This study is testing if special imaging can help doctors understand how well radiation treatments work for people with advanced prostate cancer and improve their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT06389097 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the use of SPECT imaging to evaluate the pharmacokinetics and dosimetry of radiopharmaceutical therapies in patients with advanced prostate cancer and other advanced cancers. The study aims to validate quantitative SPECT image reconstruction methods and explore the relationship between dosimetry from SPECT images and patient outcomes. A total of 80 patients will undergo SPECT/CT imaging during their treatment, with each participant imaged three times after specific cycles of therapy. The goal is to improve the understanding of radiation distribution and its effects on both tumors and normal tissues.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with advanced prostate cancer or other advanced cancers who are planning to undergo treatment with specific radiopharmaceuticals.
Not a fit: Patients currently participating in incompatible research protocols or unable to tolerate the SPECT scan procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment plans for patients undergoing radiopharmaceutical therapy.
How similar studies have performed: Other studies have shown promise in using SPECT imaging for dosimetry in radiopharmaceutical therapies, but this specific approach is innovative and aims to refine existing methods.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cohort A: Patients with advanced prostate cancer planning to undergo treatment with Radium-223 * Cohort B: Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617 \*\*Eligible patients may be planning to undergo these treatments as part of standard of care or as part of another research protocol * Age \> 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Histologic confirmation of malignancy Exclusion Criteria: * Patient is participating in another research protocol that does not allow participation in this imaging protocol or that has schedule of procedures that would not be compatible with this protocol. * Patient unable to tolerate SPECT scan time, scan frequency, or position.
Where this trial is running
Baltimore, Maryland
- Johns Hopkins University — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Ana Kiess, MD, PhD — Johns Hopkins University
- Study coordinator: Ana Kiess
- Email: akiess1@jhmi.edu
- Phone: 443-287-7528
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.